Former Walgreens exec joins Pankow Associates as account executive
SKOKIE, Ill. — Pankow Associates has hired Mark DeFilippo to serve as an account executive based in its Skokie office.
DeFilippo has had extensive experience in the industry, including 26 years with the Walgreens, where he first served as a basic department merchandiser, reorder buyer, assistant store manager and, from 1990 on, as a category manager in a variety of Walgreens purchasing departments. Over the years, his responsibilities included candy, batteries, electronics, photo finishing/photo accessories and over-the-counter products, such as cough-cold, pain and sleep remedies.
He brings to Pankow background in consumer product procurement, marketing, merchandising, inventory control, advertising, promotions, market research, pricing, product launches and strategic planning in the retail industry.
Technological tools continue to augment NACDS conferences
ALEXANDRIA, Va. — In anticipation of its upcoming 2012 Pharmacy and Technology Conference, the National Association of Chain Drug Stores has launched a mobile application to provide conference participants with a digital compass to navigate the event. The NACDS mobile website — m.NACDS.org — is also up to date with information for conference attendees.
Technological resources play an essential role in NACDS events and NACDS plans further enhancements in conference resources as it prepares for the launch of the NACDS Total Store Expo, which will be held in Las Vegas next summer. The association bills the NACDS Total Store Expo as the next generation of trade shows, referring to its format — which includes a trade show, strategic and tactical exchange, and education — as well as to its anticipated use of state-of-the-art technology to maximize the experience of participants.
The NACDS Pharmacy and Technology Conference mobile app is compatible with most smartphone platforms, including the iPhone, iPad and Android. NACDS’ mobile website — m.NACDS.org — also includes a handheld conference guide. The site provides up-to-the-minute information on conference logistics, including the schedule, floor plan and lists of participants and sponsors. Free mobile apps for iPhone, iPad and Android and information for all other smartphones are available here.
“NACDS earns its reputation for world-class meetings and conferences by putting the needs of industry members top-of-mind,” NACDS president and CEO Steve Anderson said. “Applying current technology to improve the experience of attendees is one important part of this commitment, and the feedback we are receiving is that these tools are increasingly used and valued.”
The NACDS Pharmacy and Technology Conference brings together decision makers from 130 retail companies — including chain drug stores, supermarkets and mass merchants — who collectively represent more than 80,000 retail outlets and more than $200 billion in annual sales for prescription drugs, over-the-counter medicines and home health care.
Mylan launches generic sleep disorder, bipolar disorder drugs
PITTSBURGH — Mylan has launched a generic drug used to treat sleep disorders, the company said Friday.
The generic drug maker announced the launch of modafinil tablets in the 100-mg and 200-mg strengths. The drug is a generic version of Provigil, made by Cephalon — a company that Teva Pharmaceutical Industries acquired last year — and used to treat narcolepsy, obstructive sleep apnea and shift work disorder.
There has been some contention surrounding the drug since the Food and Drug Administration determined in April that Teva was the first company to file for regulatory approval of the generic, thus entitling it to 180 days in which to compete with the branded version, as provided for under the Hatch-Waxman Act of 1984. But under an agreement with the Federal Trade Commission related to Teva’s acquisition of Cephalon, in October 2011, Par Pharmaceutical Cos. launched the generic version on April 6, while Teva launched an authorized generic, a term used to refer to the branded drug marketed under its generic name at a reduced price. Mylan responded by suing the FDA, asserting that Teva was disqualified from submitting a regulatory filing challenging Provigil’s patent protection because a company could not infringe its own patent, and that Mylan should be considered the first-to-file company.
Mylan CEO Heather Bresch said she was "pleased" that Mylan would be launching the drug prior to the expiration of the 180-day exclusivity period. Branded and generic versions of the drug had sales of about $1.3 billion during the 12-month period ended in June, according to IMS Health.
Mylan also announced the launch of lithium carbonate extended-release tablets, a drug used to treat manic episodes of bipolar disorder. Various versions of the drug had sales of about $15.2 million during the 12-month period ended in June, according to IMS.